Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SlimFuse is a transdermal weight loss patch marketed as a dietary supplement to facilitate fat reduction and appetite control. The product utilizes a sustained-release delivery system designed to administer active ingredients through the skin over a 24-hour period, bypassing the digestive system for direct systemic absorption. The formulation typically includes a blend of nutraceuticals such as *Fucus vesiculosus* (seaweed extract), Guarana, 5-Hydroxytryptophan (5-HTP), and Zinc Pyruvate. These components are intended to stimulate metabolic rate, increase energy expenditure, and promote satiety. While widely available through direct-to-consumer channels, SlimFuse is not an FDA-approved pharmaceutical medication and lacks the rigorous clinical validation required for regulated weight-loss drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SlimFuse.